PSCA hFc Chimera, Mouse
PSCA HFc Chimera, Mouse

The purity of PSCA hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC.

PSCA HFc Chimera, Mouse

PSCA hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

PSCA hFc Chimera, Mouse

Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein widely expressed in bladder, prostate, and pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer.
Z06325
¥72,752.00

Ask us a question
Product Introduction
Species Mouse
Protein Construction
hFc PSCA (Leu21-Asn95)_x000D_
Accession # P57096
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 34.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 40-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • PSCA HFc Chimera, Mouse
    • PSCA HFc Chimera, Mouse

    The purity of PSCA hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC.

  • PSCA HFc Chimera, Mouse
    • PSCA HFc Chimera, Mouse

    PSCA hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein widely expressed in bladder, prostate, and pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer.
Synonyms PSCA; UNQ206; PRO232

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.